Drug Search Results
More Filters [+]

Eslicarbazepine

Alternative Names: eslicarbazepine, s-licarbazepine, eslicarbazepinacetat, eslicarbazepin, aptiom, zebinix, exalief
Latest Update: 2023-11-08
Latest Update Note: News Article

Product Description

Eslicarbazepine is used in combination with other medications to control focal (partial) seizures (seizures that involve only one part of the brain). Eslicarbazepine is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a614032.html)

Mechanisms of Action: Sodium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Canada | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Malta | Netherlands | Norway | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: Seizures

Known Adverse Events: Ataxia | Diplopia | Dizziness | Headache | Tremor | Vertigo

Company: Bial
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eslicarbazepine

Countries in Clinic: China

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Seizures

Phase 2: Epilepsy|Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2018-002747-29

P2

Active, not recruiting

Stroke|Epilepsy

2021-09-26

2016-001072-29

P2

Completed

Epilepsy

2021-05-11

CTR20213418

P3

Not yet recruiting

Seizures

None

CTR20220017

P3

Not yet recruiting

Seizures

None

Recent News Events